Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Transgene’s Moment Of Truth Approaches

Executive Summary

French biotech Transgene SA has been through a few transformations in its 37-year history, and the past couple of years have been particularly rocky. However, chairman and CEO Philippe Archinard sees light at the end of the tunnel as the new era of combination immunotherapy arrives.

You may also be interested in...



Deal Watch: Seattle Genetics' Controversial Collaboration With Immunomedics Topples

A licensing deal between the two cancer-focused biotechs falls apart amidst investor unrest at Immunomedics. Novartis opts to license Conatus' Phase II NASH candidate and picks up a CAR-T candidate from Celyad, while Shire adds to its dry eye franchise in deal with Parion.

Transgene Secures Two Year Runway As Oncolytic Vaccine Enters Phase III

Transgene SA's share price has received a welcome boost this week on two separate pieces of news. Transgene's development partner SillaJen Inc. has begun the first Phase III trial of the oncolytic immunotherapy Pexa-Vec in patients with advanced liver cancer. Also, the company unveiled a new strategic development plan as well as the securing of €30m new financing.

Transgene Struggles With NSCLC Vaccine, Even As Positive Data Flow In

Strasbourg, France-based Transgene has presented final overall survival data from a Phase IIb trial of its non-small cell lung cancer vaccine, TG4010, confirming that the product works – but prospects for the vaccine on a competitive lung cancer market remain questionable.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097758

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel